Assessing TLS Risk in Patients Receiving Anticancer Treatment for Lymphoma or Leukemia

Use this tool to evaluate your patients’ risk for tumor lysis syndrome (TLS) to help guide management decisions.

STEP 1

Select the relevant leukemia or lymphoma cancer type1

STEP 2

Select the appropriate diagnostic lab value(s)1

Please note that the amount of information needed to determine the risk assessment will vary based on your selection of certain cancer types and lab values.

There will be a maximum of 4 selections to make.

Step 1

RISK ASSESSMENT

Overall risk for developing TLS: Intermediate1

  • Patients with low-risk disease can become intermediate-risk for TLS when renal dysfunction and/or renal involvement is present

Always use your best clinical judgment when assessing individual patient scenarios.

Antihyperuricemic prophylaxis is recommended for all patients at high or intermediate risk for TLS.1
See data for a treatment option that can help you manage uricacid levels in your patients at risk for TLS.
Explore the data
Begin new assessment

About this tool

  • This tool is only representative of a single publication; full TLS risk assessment should incorporate clinician judgment and consultation of clinical guidelines, product prescribing information, or other appropriate literature
  • This TLS Risk Assessment Tool is based on the findings of an international consensus panel of experts in pediatric and adult oncology, TLS pathophysiology, and TLS management1
  • The panel conducted a review of literature published from 1966 to 2009 regarding the incidence and treatment of TLS. Recommendations were agreed upon using both evidence-based literature and expert opinion-based approaches1

TLS is an oncologic emergency with potentially devastating consequences.1

TLS occurs spontaneously or in response to anticancer therapy and is caused by a massive release of intracellular contents into peripheral blood that results in metabolic derangements, such as1:

  • Hyperuricemia
  • Hyperkalemia
  • Hyperphosphatemia
  • Hypocalcemia

Untreated TLS may progress to cause acute renal failure, cardiac arrhythmias, loss of muscle control, seizures, or death.2

Discover a therapy with head-to-head data in the management of uric acid levels.

Visit the official HCP website
References: 1. Cairo MS, Coiffier B, Reiter A, Younes A; on behalf of the TLS Expert Panel. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149:578-586. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.5.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March 1, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.